MELISSA FRANCO: Open Payments
NPI 1801161559 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,165 in 37 payments from 11 companies in 2025. Trend: 2023 $1,932 · 2024 $4,551 · 2025 $4,165
Consulting: $2,130Food & beverage: $1,503Speaker / faculty: $500Education: $32
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 5 | $1,361 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $740 |
| Ipsen Biopharmaceuticals, Inc | 7 | $670 |
| Gilead Sciences, Inc. | 9 | $604 |
| GlaxoSmithKline, LLC. | 2 | $500 |
| Novo Nordisk Inc | 2 | $60 |
| Aimmune Therapeutics, Inc. | 2 | $59 |
| Intercept Pharmaceuticals, Inc. | 2 | $57 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Phathom Pharmaceuticals, Inc. | 1 | $37 |
Products named: REZDIFFRA, XIFAXAN, IQIRVO, ZENPEP, OCALIVA, INSPIRE, VOQUEZNA, TREMFYA.
Industry payments across FL — which companies pay providers there.
